Citations

Clear

9383 citation(s) found for "Thomas, PS".

An Unusual Foreign Body in the Urinary Bladder Mimicking a Parasitic Worm
Schmitt, Bryan H., Feder, Marc, Rokke, Denise L., Moyer, Thomas P. , Pritt, Bobbi S. , Rokke, Denise, Pritt, Bobbi S

Mayo Clinic

Journal of Clinical Microbiology | April 27, 2012 | Volume: 50 | Issue: 7 | Pages: 2520-2522

10.1128/jcm.00532-12 | PMID 22535991 Get It

ABSTRACTWe report an unusual case of a foreign body removed from the urinary bladder of a 63-year-old male which mimicked a parasitic worm. The foreign body was identified as an artificial fishing worm by morphological comparison to a similar commercially produced product and by infrared spectrum analysis.
The role of genetic breast cancer susceptibility variants as prognostic factors
Fasching, Peter A. , Cox, Angela , Nevanlinna, Heli , Bojesen, Stig E. , Karn, Thomas , Leeuwen, Flora E. van , Veer, Laura van ‘t , Udo, Renate, Dunning, Alison M. , Greco, Dario , Aittomäki, Kristiina, Blomqvist, Carl , Shah, Mitul , Nordestgaard, Børge G. , Flyger, Henrik, Hopper, John L. , Southey, Melissa C. , Apicella, Carmel, García‐Closas, Montserrat , Sherman, Mark E., Lissowska, Jolanta , Seynaeve, Caroline, Huijts, Petra E.A., Tollenaar, Rob A.�E.�M. , Ekici, Arif B. , Rauh, Claudia , Mannermaa, Arto, Kataja, Vesa , Kosma, Veli-Matti, Hartikainen, Jaana M. , Andrulis, Irene L. , Özçelik, Hilmi, Mulligan, Anna Marie , Glendon, Gord, Czene, Kamila , Liu, Jianjun , Chang‐Claude, Jenny , Wang‐Gohrke, Shan , Eilber, Ursula, Nickels, Stefan , Dörk, Thilo , Schiekel, Maria, Bremer, Michael , Park‐Simon, Tjoung‐Won, Giles, Graham G. , Severi, Gianluca , Baglietto, Laura , Hooning, Maartje J. , Jager, Agnes , Kriege, Mieke, Lindblom, Annika , Margolin, Sara , Stevens, Kristen N., Kosel, Matthew , Cross, Simon S. , Balasubramanian, Sabapathy P. , Reed, Malcolm , Miron, Alexander, John, Esther M. , Winqvist, Robert , Pylkäs, Katri , Jukkola‐Vuorinen, Arja , Kauppila, Saila , Burwinkel, Barbara , Schneeweiß, Andreas , Sohn, Christof , Chenevix‐Trench, Georgia , Investigators, kConFab, Lambrechts, Diether , Dieudonné, Anne-Sophie, Hatse, Sigrid , Limbergen, Erik Van, Zamora, M. Pilar , Peissel, Bernard , Loris, Bernard, Peterlongo, Paolo , Rajaraman, Preetha , Beckmann, Matthias W. , Slamon, Dennis J. , Phillips, Kelly‐Anne , Humphreys, Manjeet K., Easton, Douglas F. , Schmidt, Marjanka K. , Thorne, Heather , Purrington, Kristen S. , Lambrechts, Diether , Pharoah, Paul D.P. , Broeks, Annegien , Veer, Laura J. van’t , Ziogas, Argyrios , Mannermaa, Arto, Hall, Per N , Martens, John W.M. , Couch, Fergus J. , Olson, Janet E. , Marmé, Frederik , Investigators, kConFab, Benı́tez, Javier , Milne, Roger L. , Pérez, José Ignacio Arias , Bonanni, Bernardo , Schonfeld, Sara J. , Anton‐Culver, Hoda , Devilee, Peter , Figueroa, Jonine D. , Nevanlinna, H , Dörk, Thilo , Lambrechts, Diether , Giles, Graham G , Peterlongo, Paolo , Lissowska, Jolanta , John, Esther M , Southey, Melissa C , Dunning, Alison M , Lambrechts, Diether , Cox, Angela , García-Closas, Montserrat , Schmidt, Marjanka K , Severi, Gianluca , Ekici, Arif B , Hartikainen, Jaana M , Chenevix-Trench, Georgia , Czene, Kamila , Pylkäs, Katri , Baglietto, Laura , Bojesen, Stig E , Purrington, Kristen S , Phillips, Kelly-Anne , Lindblom, Annika , Liu, Jing

Mayo Clinic

Human Molecular Genetics | April 25, 2012 | Volume: 21 | Issue: 17 | Pages: 3926-3939

10.1093/hmg/dds159 | PMID 22532573 Get It

miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia
Eisfeld, Ann‐Kathrin , Marcucci, Guido , Maharry, Kati , Schwind, Sebastian , Radmacher, Michael D., Becker, Heiko , Mrózek, Krzysztof , Whitman, Susan P., Metzeler, Klaus H. , Mendler, Jason H. , Wu, Yue-Zhong, Liyanarachchi, Sandya , Baer, Maria R. , Powell, Bayard L., Carter, Thomas H. , Moore, Joseph O. , Kolitz, Jonathan E. , Wetzler, Meir , Larson, Richard A. , Tanner, Stephan M., Chapelle, Albert de la , Bloomfield, Clara D. , Nicolet, Deedra , Patel, Ravi Kumar , Caligiuri, Michael A. , Larson, Richard A

Mayo Clinic

Blood | April 24, 2012 | Volume: 120 | Issue: 2 | Pages: 249-258

10.1182/blood-2012-02-408492 | PMID 22529287 Get It

Abstract High BAALC expression levels are associated with poor outcome in cytogenetically normal acute myeloid leukemia (CN-AML) patients. Recently, miR-3151 was discovered in intron 1 of BAALC. To evaluate the prognostic significance of miR-3151 expression levels and to gain insight into the biologic and prognostic interplay between miR-3151 and its host, miR-3151 and BAALC expression were measured in pretreatment blood of 179 CN-AML patients. Gene-expression profiling and miRNA-expression profiling were performed using microarrays. High miR-3151 expression was associated with shorter disease-free and overall survival, whereas high BAALC expression predicted failure of complete remission and shorter overall survival. Patients exhibiting high expression of both miR-3151 and BAALC had worse outcome than patients expressing low levels of either gene or both genes. In gene-expression profiling, high miR-3151 expressers showed down-regulation of genes involved in transcriptional regulation, posttranslational modification, and cancer pathways. Two genes, FBXL20 and USP40, were validated as direct miR-3151 targets. The results of the present study show that high expression of miR-3151 is an independent prognosticator for poor outcome in CN-AML and affects different outcome end points than its host gene, BAALC. The combination of both markers identified a patient subset with the poorest outcome. This interplay between an intronic miR and its host may have important biologic implications.
Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: [RETIRED]
Holland, Starr, Silberstein, Stephen D., Freitag, F. G., Argoff, Charles E. , Ashman, Eric, Ibáñez, Agustín , Dodick, David W. , Ibañez, Agustín

Mayo Clinic

Neurology | April 23, 2012 | Volume: 78 | Issue: 17 | Pages: 1346-1353

10.1212/wnl.0b013e3182535d0c | PMID 22529203 Get It

Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults
Holland, Starr, Freitag, F. G., Argoff, Charles E. , Ashman, Eric, Silberstein, Stephen D. , Dodick, David W.

Mayo Clinic

Neurology | April 23, 2012 | Volume: 78 | Issue: 17 | Pages: 1337-1345

10.1212/wnl.0b013e3182535d20 | PMID 22529202 Get It

Predicting missing biomarker data in a longitudinal study of Alzheimer disease
Lo, Raymond Y. , Jagust, William J. , Aisen, Paul , Gamst, Anthony, Soares, Holly , Montine, Tom, Thomas, Ronald G. , Walter, Sarah , Felmlee, Joel P. , Schuff, Norbert, Alexander, Gene, DeCarli, Charles , Bandy, Dan, Korecka, Magdalena , Crawford, Karen , Neu, Scott, Kornak, John , Buckholtz, Neil, Dolen, Sara, Schneider, Lon S. , Pawluczyk, Sonia, Spann, Bryan M., Brewer, James, Vanderswag, Helen, Heidebrink, Judith L. , Petersen, Ronald , Johnson, Kris , Doody, Rachelle S., Villanueva‐Meyer, Javier , Chowdhury, Munir , Bell, Karen L. , Mintun, Mark A., Schneider, Stacy, Marson, Daniel , Griffith, Randall, Grossman, Hillel, Marzloff, George, Toledo-Morrell, Leylade, Duara, Ranjan , Varón, Daniel , Roberts, Peggy, Albert, Marilyn S. , Pedroso, Julia, Toroney, Jaimie, Santi, Susan M De, Doraiswamy, P. Murali , Petrella, Jeffrey R. , Aiello, Marilyn, Clark, Christopher M. , Pham, Cassie, Nuñez, Jessica, Smith, Charles D., Given, Curtis A., Hardy, Peter , Oakley, MaryAnn, Simpson, Donna M., Ismail, M. Saleem , Brand, Connie, Richard, Jennifer, Mulnard, Ruth A., Thai, Gaby , Mc-Adams-Ortiz, Catherine, Martin-Cook, Kristen, Devous, Michael D. , Cellar, Janet S., Anderson, Heather S., Laubinger, Mary M., Bartzokis, George, Lu, Po H. , MBBCH, Neill R Graff-Radford, Parfitt, Francine, Farlow, Martin R. , Herring, Scott, Hake, Ann Marie , Dyck, Christopher H. van , MacAvoy, Martha G., Benincasa, Amanda L., Chertkow, Howard, Bergman, Howard , Hosein, Chris, Graham, Simon J. , Caldwell, Curtis, Hsiung, Ging‐Yuek Robin , Assaly, Michele, Kertesz, Andrew, Rogers, John, Trost, Dick, Bernick, Charles , Munic, Donna, Wu, Chuang‐Kuo, Johnson, Nancy , Mesulam, Marsel, Sadowsky, Carl, Villena, Teresa, Turner, Scott, Johnson, Kathleen, Behan, Kelly E., Johnson, Keith A. , Rosen, Allyson , Tinklenberg, Jared, Ashford, Wes, Sabbagh, Marwan N. , Connor, Donald J., Jacobson, Sandra A. , Jayam‐Trouth, Annapurni , Lerner, Alan J. , Hudson, Leon, Ogrocki, Paula, Fletcher, Evan, Kittur, Smita, Mirje, Seema, Borrie, Michael, Lee, T‐Y, Bartha, Dr Rob, Asthana, Sanjay , Carlsson, Cynthia M., Potkin, Steven, Preda, Adrian , Tariot, Pierre N. , Fleisher, Adam , Reeder, Stephanie, Bates, Vernice, Capote, Horacio, Rainka, Michelle, Hendin, Barry , Kataki, Maria , Zimmerman, Earl A. , Celmins, Dzintra, Brown, Alice D., Marenberg, Marjorie E., Rovner, Barry W. , Anderson, Karen, Santulli, Robert B. , Englert, Jessica, Williamson, Jeff D. , Watkins, Franklin, Ott, Brian R. , Cohen, Ronald, Salloway, Stephen , Malloy, Paul, Correia, Stephen , Rosen, Howard J. , Mintzer, Jacobo , Jack, Clifford R. , Toga, Arthur W. , Beckett, Laurel , Green, Robert C. , Donohue, Michael , Dale, Anders M. , Bernstein, Matt A. , Fox, Nick C. , Thompson, Paul M. , Chen, Kewei , Morris, John C. , Lee, Virginia M.‐Y. , Harvey, Danielle , Saykin, Andrew J. , Foroud, Tatiana , Potkin, Steven G. , Shen, Li , Kaye, Jeffrey , Quinn, Joseph F. , Lord, Joanne L. , Stern, Yaakov , Honig, Lawrence S. , Clark, David , Tang, Cheuk Ying , Shah, Raj C. , Duara, Ranjan , Rusinek, Henry , Leon, Mony J. de , López, Oscar L. , Diaz‐Arrastia, Ramon , Levey, Allan I. , Lah, James J. , Burns, Jeffrey M. , Silverman, Daniel H.S. , Johnson, Heather K. , Black, Sandra E. , Feldman, Howard , Martínez, Walter Fabián , Sperling, Reisa Anne , Rentz, Dorene M. , Killiany, Ronald , Norbash, Alexander , Nair, Anil K. , Obisesan, Thomas O. , Wang, Paul C. , Carmichael, Owen , Johnson, Sterling C. , Nguyen, Dana R. , Reeder, Stephanie, Scharre, Douglas W. , Gandy, Sam , Pearlson, Godfrey D. , Sink, Kaycee M. , Miller, Bruce L. , Preda, Adrian , Hsiung, Gink-Yuek

Mayo Clinic

Neurology | April 5, 2012 | Volume: 78 | Issue: 18 | Pages: 1376-1382

10.1212/wnl.0b013e318253d5b3 | PMID 22491869 Get It

Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis
Dispenzieri, Angela , Laumann, Kristina, LaPlant, Betsy, Hayman, Suzanne R. , Kumar, Shaji , Dingli, David , Zeldenrust, Steven R., Hall, Robert L., Rajkumar, S. Vincent , Reeder, Craig B. , Fonseca, Rafaël , Bergsagel, P. Lief, Stewart, A. Keith, Lust, John A., Russell, Stephen J. , Lacy, Martha Q. , Bergsagel, P. Leif , Buadi, Francis K. , Mıkhael, Joseph , Roy, Vivek , Witzig, Thomas E. , Gertz, Morie A. , Bergsagel, P. Leif , Rajkumar, S Vincent , Dispenzieri, Angela , Russell, Stephen J , Dingli, David , Fonseca, Rafael

Mayo Clinic

Blood | April 4, 2012 | Volume: 119 | Issue: 23 | Pages: 5397-5404

10.1182/blood-2012-02-413161 | PMID 22493299 Get It

Abstract Immunoglobulin light-chain (AL) amyloidosis is a rare, incurable plasma cell disorder. Its therapy has benefited immensely from the expanding drug armamentarium available for multiple myeloma. Pomalidomide in combination with weekly dexamethasone (Pom/dex) is active among patients with relapsed myeloma. In the present study, we explored the Pom/dex combination in patients with previously treated AL. Patients were eligible for this prospective phase 2 trial if they had had at least one prior regimen and if they had reasonably preserved organ function. Patients were treated with oral Pom/dex. Thirty-three patients were enrolled. The median age was 66 years. Median time from diagnosis to on-study was 37 months. Eighty-two percent had cardiac involvement. The confirmed hematologic response rate was 48%, with a median time to response of 1.9 months. Organ improvement was documented in 5 patients. The median overall and progression-free survival rates were 28 and 14 months, respectively; the 1-year overall and progression-free survival rates were 76% and 59%, respectively. There was a discordance between the hematologic response and the N-terminal pro-brain natriuretic peptide response. The most common grade 3-5 adverse events, regardless of attribution, were neutropenia and fatigue. We conclude that pomalidomide appears to be a valuable drug covering an unmet clinical need in patients with previously treated AL. The trial is registered at www.clinicaltrials.gov as NCT00558896.
What are the keys to successful thyroid FNA interpretation?
Sebo, Thomas J.

Mayo Clinic

Clinical Endocrinology | April 3, 2012 | Volume: 77 | Issue: 1 | Pages: 13-17

10.1111/j.1365-2265.2012.04404.x | PMID 22469035 Get It

SummaryThere is much concern expressed in the literature regarding the lack of predictive power of the thyroid fine needle aspiration/biopsy (TFNAB) approach to defining the nature of clinically detected thyroid nodules. This has been exacerbated in the past decade or more by the routine use of ultrasonography (US) in examining the thyroid as well as the introduction of molecular testing in the realm of thyroid pathology. Some have even gone so far as to suggest replacing the TFNAB with molecular signature testing to reduce the degree of uncertainty for a specific cytological diagnosis. This review addresses those concerns with a re‐emphasis on understanding the basic keys to successfully evaluating a patient with a thyroid nodule by routine TFNAB examination. These keys include bringing to bear an experienced group of physicians in an integrated team approach, a sharpened focus on the TFNAB cytological categories and a grounded understanding of the predictive ability of molecular testing in a given patient when the cytological interpretation creates too much uncertainty in the minds of the patients and clinicians in attempting to reach a decision on how to manage a thyroid nodule. With this practical approach in mind, the false‐negative and false‐positive rates of “negative (benign)” and “positive (malignant)” thyroid aspirates should be no more than 1%; and the prevalence of an “indeterminate” aspirate – the area in TFNAB attracting the most attention for improvement with novel biomarkers – should be 10% or less. Thus, physicians should be capable of managing at least 90% of patients undergoing TFNAB in a confident manner without further testing beyond the routine, future re‐examination of the patient's nodule to re‐assess for any change in its nature or its impact on the patient's quality of life. The other 10% can then be considered for molecular testing in a manner tailored to those individuals truly in need of a more sophisticated – and expensive – approach to the characterization of their thyroid nodules. As the era of US has matured – just as with the era of serum PSA testing for prostate cancer in men – we have experienced a paradigm shift: Given the incidence of thyroid nodules in the U.S. adult population in comparison with the risk of dying of thyroid malignancy, the main role of TFNAB is to reduce the need for surgical intervention.
Janus kinase Inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure?
Harrison, Claire , Verstovšek, Srđan , McMullin, Mary Frances , Mesa, Ruben A. , Verstovsek, Srdan

Mayo Clinic

British Journal of Haematology | March 31, 2012 | Volume: 157 | Issue: 4 | Pages: 426-437

10.1111/j.1365-2141.2012.09108.x | PMID 22463737 Get It

SummaryFollowing the discovery of the Janus kinase (JAK) 2 V617F mutation in 2005 the explosion of research and drug development activity has not only advanced our understanding of the pathogenesis of myeloproliferative neoplasms (MPNs) but also triggered debate about classification, allowed revised diagnostic and response criteria, provided a target for treatment and a mode of monitoring its success. These changes and the resultant clinical research are discussed in this article where we argue that discovery of the JAK2 V617F mutation has signalled the much delayed change in therapeutic paradigm for myelofibrosis and possibly other MPNs from palliation and allowing us to move closer to, but not yet attain, a cure.